find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
43
Clinical Trials
Multiple Myeloma
N/A
Enrolling
nct/study# N/A / 2021-0269
Real-World Outcomes of Patients with Penta-Refractory Multiple Myeloma
Learn More
Multiple Myeloma
N/A
Enrolling
nct/study# NCT03763370 / 2023-GSKEAP-213304
Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody
Learn More
Multiple Myeloma
Phase III
Enrolling
nct/study# NCT06208150 / 64407564MMY3009
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
Learn More
Multiple Myeloma
N/A
Enrolling
nct/study# N/A / ABSCOPAL-EMD-MYELOMA
Evaluate Abscopal Effect Using Radiation Therapy and Immune Checkpoint Inhibitors for Patients with Extramedullary Myeloma Disease
Learn More
Multiple Myeloma
N/A
Enrolling
nct/study# N/A / 2021-0121
Characterization and treatment of daratumumab-associated infections in patients with multiple myeloma.
Learn More
Multiple Myeloma
Phase I
Enrolling
nct/study# NCT05722418 / CB11A
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.